RecallRadar

FDA Drug recall D-0381-2026

Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cip…

On 2026-03-11 the FDA classified a Class III recall of Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cip… by Cipla Usa, citing failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0381-2026
ClassificationClass III
Statusongoing
Initiated2026-02-18
Published2026-03-11
Last updated2026-09-13 11:52 UTC
CompanyCipla Usa
DistributionUS

Product

Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17

Reason

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Identifiers

ndc69097-030-08
ndc69097-030-16
ndc69097-030-63
ndc69097-031-17
ndc69097-031-56
ndc69097-031-74
ndc69097-031-76
ndc69097-031-73
ndc69097-031-91
ndc69097-032-17
ndc69097-032-56
ndc69097-032-74
ndc69097-032-76
ndc69097-032-73
ndc69097-032-91
code_infoLot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0381-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.